Market Overview

UPDATE: Piper Jaffray Raises PT to $48 on Medtronic on Solid Quarter, Conservative Guidance

Share:
Related MDT
Oppenheimer Previews Medtronic's Q4 Earnings, Remains Bullish
Medtronic And Qualcomm To Develop Continuous Glucose Monitoring System
The Vetr community has downgraded $MDT to 3-Stars (Vetr)

Piper Jaffray reiterated its Overweight rating on Medtronic (NYSE: MDT) and raised its price target from $45 to $48.

Piper Jaffray noted, "While FY13 revenue guidance increased from 2%-4% to 3%-4%, guidance assumes a deceleration in sequential 2H13 growth (vs. 5% cc growth in F1H13). We view this as conservatism on the part of MDT's CEO, and believe this is appropriate given macro headwinds and product specific challenges. GMs were softer than expected, despite strong revenues, perpetuating the discussion on the leverage sustainability, especially given MDT's focus on EM growth. However, we note that the lower end of guidance did come up, and appreciate the renewed focus on meeting expectations. Overall, we view the results as positive."

Medtronic closed at $41.81 on Tuesday.

Latest Ratings for MDT

DateFirmActionFromTo
Apr 2016SunTrust Robinson HumphreyInitiates Coverage onBuy
Mar 2016NomuraInitiates Coverage onBuy
Mar 2016Morgan StanleyMaintainsOverweight

View More Analyst Ratings for MDT
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (MDT)

View Comments and Join the Discussion!